Contact this trialFirst, we need to learn more about you.
Corticosteroid
Lenalidomide-Dexamethasone-DLI for Multiple Myeloma
Recruiting1 awardPhase 2
Montréal, Quebec
This trial is a two-step treatment using Lenalidomide and Dexamethasone followed by Donor Leukocyte Infusions to offer an optimal disease control strategy in relapsed patients. The cytoreductive and immunomodulatory effects of Len are expected to induce a permissive immunological environment for the immunotherapeutic activity of DLIs to develop. This treatment combination has the potential to further improve depth of myeloma response, delay myeloma progression and improve patient survival.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.